Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01679028 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese
A Phase 1 study, sponsored by Tasly Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01679028 is a Phase 1 study that has completed, run by Tasly Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT01679028, a Phase 1 study, has completed, sponsored by Tasly Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to see how safe an investigational new drug (T89) is and how well healthy Japanese subjects tolerate it when given two single doses and a multiple dose.
Interventions
- DRUG T89 Group A
- DRUG Placebo Group A
- DRUG Placebo Group B
- DRUG T89 Group B
- DRUG Placebo Group C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01679028
The ClinicalTrials.gov registry entry for NCT01679028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tasly Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which T89 Group A is the first listed.
NCT01679028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01679028 about?
NCT01679028 is a clinical study titled "Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese". The purpose of this study is to see how safe an investigational new drug (T89) is and how well healthy Japanese subjects tolerate it when given two single doses and a multiple dose.
What is the current status of trial NCT01679028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-08. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01679028?
The interventions under investigation include: T89 Group A (DRUG), Placebo Group A (DRUG), Placebo Group B (DRUG), T89 Group B (DRUG), Placebo Group C (DRUG).
Who is sponsoring clinical trial NCT01679028?
This trial is sponsored by Tasly Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.